Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMIX NASDAQ:CODX NASDAQ:HSCS NASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$2.92-16.6%$6.95$2.90▼$32.55$1.59M-1.32230,123 shs7.99 million shsCODXCo-Diagnostics$2.10-5.0%$3.89$1.26▼$46.50$7.74M2.84533,779 shs126,381 shsHSCSHeartSciences$2.39-2.0%$2.27$1.63▼$4.30$7.61M1.7886,167 shs8,205 shsQNRXQuoin Pharmaceuticals$4.28-2.1%$4.57$3.25▼$41.80$8.60M1.5245,994 shs6,227 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical0.00%-34.38%-54.23%-62.26%-90.21%CODXCo-Diagnostics0.00%-14.63%-31.15%+25.75%-75.72%HSCSHeartSciences0.00%-11.15%-20.07%+16.59%-37.60%QNRXQuoin Pharmaceuticals0.00%+0.94%+1.90%-24.91%-49.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$2.92-16.6%$6.95$2.90▼$32.55$1.59M-1.32230,123 shs7.99 million shsCODXCo-Diagnostics$2.10-5.0%$3.89$1.26▼$46.50$7.74M2.84533,779 shs126,381 shsHSCSHeartSciences$2.39-2.0%$2.27$1.63▼$4.30$7.61M1.7886,167 shs8,205 shsQNRXQuoin Pharmaceuticals$4.28-2.1%$4.57$3.25▼$41.80$8.60M1.5245,994 shs6,227 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical0.00%-34.38%-54.23%-62.26%-90.21%CODXCo-Diagnostics0.00%-14.63%-31.15%+25.75%-75.72%HSCSHeartSciences0.00%-11.15%-20.07%+16.59%-37.60%QNRXQuoin Pharmaceuticals0.00%+0.94%+1.90%-24.91%-49.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMIXAutonomix Medical 2.00Hold$42.001,338.36% UpsideCODXCo-Diagnostics 2.00Hold$67.503,114.29% UpsideHSCSHeartSciences 2.00Hold$8.00234.73% UpsideQNRXQuoin Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest AMIX, CODX, QNRX, and HSCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026QNRXQuoin Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/10/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/24/2026HSCSHeartSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/23/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/15/2026QNRXQuoin Pharmaceuticals ThinkEquitySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/11/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/2/2026AMIXAutonomix Medical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/26/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/4/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMIXAutonomix MedicalN/AN/AN/AN/A$10.85 per shareN/ACODXCo-Diagnostics$620K12.50N/AN/A$9.14 per share0.23HSCSHeartSciencesN/AN/AN/AN/A$0.18 per shareN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/A$15.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMIXAutonomix Medical-$16.72M-$74.58N/AN/AN/AN/A-239.36%-192.46%8/12/2026 (Estimated)CODXCo-Diagnostics-$46.90M-$15.77N/AN/AN/A-6,760.63%-164.92%-141.15%8/14/2026 (Estimated)HSCSHeartSciences-$8.77M-$3.94N/AN/AN/AN/A-275.02%-137.21%9/10/2026 (Estimated)QNRXQuoin Pharmaceuticals-$15.81M-$29.56N/AN/AN/AN/A-489.85%-221.29%8/6/2026 (Estimated)Latest AMIX, CODX, QNRX, and HSCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026CODXCo-Diagnostics-$3.00N/AN/AN/A$0.13 millionN/A8/12/2026Q1 2027AMIXAutonomix Medical-$6.4050N/AN/AN/AN/AN/A8/6/2026Q2 2026QNRXQuoin Pharmaceuticals-$1.61N/AN/AN/AN/AN/A7/23/2026Q4 2026HSCSHeartSciences-$0.66-$0.88-$0.22-$0.87$0.05 millionN/A5/14/2026Q1 2026CODXCo-Diagnostics-$3.75-$4.06-$0.31-$4.06$0.13 million$0.15 million5/7/2026Q1 2026QNRXQuoin Pharmaceuticals-$2.17-$1.77+$0.40-$1.77N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMIXAutonomix MedicalN/AN/AN/AN/AN/ACODXCo-DiagnosticsN/AN/AN/AN/AN/AHSCSHeartSciencesN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMIXAutonomix MedicalN/A4.454.45CODXCo-DiagnosticsN/A2.282.09HSCSHeartSciences0.161.191.04QNRXQuoin PharmaceuticalsN/A2.872.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMIXAutonomix Medical10.78%CODXCo-Diagnostics14.99%HSCSHeartSciences17.24%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipAMIXAutonomix Medical6.20%CODXCo-Diagnostics5.40%HSCSHeartSciences4.90%QNRXQuoin Pharmaceuticals11.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMIXAutonomix Medical1540,000509,000N/ACODXCo-Diagnostics1003.69 million3.49 millionOptionableHSCSHeartSciences103.18 million3.03 millionNot OptionableQNRXQuoin Pharmaceuticals42.01 million1.78 millionNot OptionableAMIX, CODX, QNRX, and HSCS HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin SyndromeJuly 9, 2026 | finanznachrichten.deQuoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin SyndromeJuly 9, 2026 | globenewswire.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton SyndromeJune 30, 2026 | finanznachrichten.deQuoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton SyndromeJune 30, 2026 | globenewswire.comQuoin Pharmaceuticals Ltd (NASDAQ: QNRX) - Share Price and ResearchJune 24, 2026 | intelligentinvestor.com.auIQuoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton SyndromeJune 23, 2026 | globenewswire.comQuoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003June 18, 2026 | globenewswire.comQuoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use ProgramJune 16, 2026 | globenewswire.comQuoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton SyndromeJune 4, 2026 | globenewswire.comQuoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin SyndromeJune 2, 2026 | globenewswire.comQuoin Pharmaceuticals. Ltd Sponsored ADRMay 19, 2026 | edition.cnn.comQuoin Pharmaceuticals (QNRX) Receives a Buy from Maxim GroupMay 9, 2026 | theglobeandmail.comQuoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comQuoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026April 30, 2026 | globenewswire.comCORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsApril 28, 2026 | globenewswire.comQuoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsApril 28, 2026 | globenewswire.comQNRX: Preparing to Commercialize Lead Asset Through Global Sales InfrastructureApril 15, 2026 | msn.comMaxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX)April 11, 2026 | theglobeandmail.comQuoin Pharmaceuticals - Depositary Receipt (QNRX) price target increased by 12.66% to 30.26April 10, 2026 | msn.comQuoin Pharmaceuticals - Depositary Receipt (QNRX) price target decreased by 36.80% to 26.86March 27, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMIX, CODX, QNRX, and HSCS Company DescriptionsAutonomix Medical NASDAQ:AMIX$2.92 -0.58 (-16.57%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.09 +0.17 (+5.89%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Co-Diagnostics NASDAQ:CODX$2.10 -0.11 (-4.98%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.07 -0.03 (-1.38%) As of 07/24/2026 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.HeartSciences NASDAQ:HSCS$2.39 -0.05 (-2.05%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.36 -0.04 (-1.46%) As of 07/24/2026 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.Quoin Pharmaceuticals NASDAQ:QNRX$4.28 -0.09 (-2.06%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.12 -0.16 (-3.76%) As of 07/24/2026 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
